Emphysema Chronic Obstructive Pulmonary Disease Research Articles

Potential health impacts and lung microbiome changes among smoking and smokeless tobacco use : A technical scan

Globally, 1.3 billion peoples use tobacco products daily, most of them from low- and middle-income countries. Every year, 8 million of the population died because of the usage of tobacco, as per the WHO report. Tobacco-related diseases, likely lung cancer, emphysema chronic obstructive pulmonary disease, and chronic respiratory diseases, are more common. Nicotine is a highly addictive chemical found in the tobacco plant and also in all other tobacco products. All tobacco products contain nicotine that causes the release of dopamine in the pleasure and motivation areas of the brain. Both smoking and smokeless tobacco products contain many harmful chemicals that affect the lung mucociliary clearance and also inactivate the immune system and lead to increases in the risk of infection and the development of deleterious bacterial growth in the lungs. In the lung microbiome, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa bacterial species were found to a higher level in smoking tobacco users as that may increase morbidity and mortality. The lung microbiome changes taking place in the lung due to smokeless tobacco usage are less documented so far. In future research, microbiome studies help to understand disease pathogenesis.

Analysis of Bronchoscopy on Acute Exacerbation of Pulmonary Emphysema Chronic Obstructive Pulmonary Disease Using CT Chest Imaging

Purpose: To understand the role of bronchoscopy in the treatment of chest CT images for patients with acute exacerbation of emphysema phenotype chronic obstructive pulmonary disease (COPD). Methods: 89 cases with chest CT images suggesting acute exacerbation of emphysema phenotype COPD were included and divided into the experimental group and the control group according to whether underwent bronchoscopy. Arterial blood gas indexes (pH value, PaO2, PaCO2), total glucocorticoid usage, length of stay, serum inflammatory factors (TNF-α, IL-6, IL-10) before and after treatment were compared between the two groups. Results: The hospitalization time of the experimental group was significantly shorter than that of the control group (11.88 ± 8.61 d vs. 16.50 ± 12.15 d, P = 0 045); the total use of methylprednisolone test group was 213.66 ± 32.07mg, and the control group was 250.83 ± 102.55 mg. The difference between the two groups was statistically significant (P = 0 028). The trend of repeated analysis of variance (F = 12 11,P = 0 001) were statistically significant. PaCO2 significantly decreased before and after the test in the experimental group (49.40 14.85 mmhg vs. 43.30 12.48 mmhg, P = 0.000). Plasma TNF-α and IL-6 decreased and IL-10 increased before and after the test. TNF-α and IL-6 increased and IL-10 decreased before and after the control group test, and the changes and trends of TNF-α, IL-6 and IL-10 before and after the two groups were statistically different (P = 0.000). These symptoms can be analyzed using CT imaging. Conclusion: In patients with acute exacerbation of emphysema phenotype COPD who are initially ineffective, bronchoscopy, alveolar lavage, and anti-contamination brush sampling guide anti-infective treatment can improve patient ventilation, and reduce glucocorticoid consumption.

Lung Volume Reduction Surgery After Lung Transplantation for Emphysema—Chronic Obstructive Pulmonary Disease

Lung Volume Reduction Surgery (LVRS) has become a palliative treatment for patients with advanced emphysema and disabling dyspnea. After single lung transplantation in chronic obstructive pulmonary disease, LVRS may be indicated to improve graft dysfunction caused by native lung hyperinflation compressing the grafted lung. This common complication is the subject of our study, which showed LVRS to be helpful to manage this situation. We performed an observational retrospective and descriptive study using the data of 293 patients transplanted in our center between January 1996 and October 2011. Some of the patients who underwent a single lung transplantation developed native lung hyperinflation years after the transplantation, interfering with respiratory function due to graft compression.